QURE Stock Recent News

~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~

The consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

uniQure N.V. (NASDAQ:QURE ) Q2 2025 Earnings Call July 29, 2025 8:30 AM ET Company Participants Chiara Russo - Senior Director of Investor Relations Matthew Kapusta - CEO & Executive Director Walid Abi-Saab - Chief Medical Officer Christian Klemt - CFO, Principal Financial Officer & GM of Amsterdam Site Conference Call Participants Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Thome - TD Cowen, Research Division Sushila Hernandez - Van Lanschot Kempen Luca Issi - RBC Capital Markets, Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Samantha Corwin - William Blair & Company L.L.C.

uniQure Narrows Loss in Fiscal Q2

uniQure (QURE) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $1.16 per share a year ago.

~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026;

uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET

~ Proven biotech executive to lead commercialization of AMT-130 in Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V.

~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass.

uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA's Breakthrough Therapy, RMAT, Fast-Track, and Orphan Drug status with Accelerated Approval via cUHDRS. Similarly, QURE is building MRI-guided infusion centers, payer-access teams, and a US Center of Excellence network. All of these moves prove management's high confidence in AMT-130.